ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 277 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,792 | -32.7% | 811 | -10.7% | 0.00% | – |
| Q2 2023 | $32,379 | -98.6% | 908 | -98.4% | 0.00% | -100.0% |
| Q4 2022 | $2,297,805 | -89.6% | 56,652 | -91.5% | 0.01% | -90.9% |
| Q3 2022 | $22,031,000 | +58.1% | 666,600 | +68.4% | 0.09% | +49.2% |
| Q2 2022 | $13,939,000 | -46.0% | 395,868 | -29.4% | 0.06% | -42.2% |
| Q1 2022 | $25,805,000 | +778.6% | 561,100 | +1166.8% | 0.10% | +750.0% |
| Q4 2021 | $2,937,000 | -70.7% | 44,292 | -72.4% | 0.01% | -72.7% |
| Q3 2021 | $10,020,000 | +116.4% | 160,500 | +187.1% | 0.04% | +109.5% |
| Q2 2021 | $4,630,000 | -91.9% | 55,900 | -95.8% | 0.02% | -92.9% |
| Q3 2020 | $57,395,000 | +11.7% | 1,332,899 | +12.0% | 0.29% | -12.2% |
| Q2 2020 | $51,388,000 | +30671.3% | 1,189,807 | +12979.1% | 0.34% | +33400.0% |
| Q1 2019 | $167,000 | +169.4% | 9,097 | +7.0% | 0.00% | – |
| Q3 2016 | $62,000 | -95.4% | 8,500 | -96.7% | 0.00% | -100.0% |
| Q2 2016 | $1,362,000 | – | 256,101 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |